Market Filing: Why Seth Klarman’s Baupost Group LlcMa Reported Big Kindred Biosciences, Inc Position?

Market Filing: Why Seth Klarman's Baupost Group LlcMa Reported Big Kindred Biosciences, Inc Position?

The New Seth Klarman’s Baupost Group LlcMa Holding in Kindred Biosciences, Inc

Baupost Group LlcMa filed with the SEC SC 13G/A form for Kindred Biosciences, Inc. The form can be accessed here: 000114036116085606. As reported in Seth Klarman’s Baupost Group LlcMa’s form, the filler as of late owns 4.85% or 965,484 shares of the Health Care–company.

Kindred Biosciences, Inc stake is a new one for the for the hedge fund and it was filed because of activity on October31,2016. We feel this shows Seth Klarman’s Baupost Group LlcMa’s positive view for the stock. For a hedge fund managing $29.88 billion in assets and having 202+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Seth Klarman’s Baupost Group LlcMa’s US equities portfolio is in this sector.

Kindred Biosciences, Inc Institutional Sentiment

Latest Security and Exchange filings show 44 investors own Kindred Biosciences, Inc. The institutional ownership in Q3 2015 is low, at 60.74% of the outstanding shares. This is increased by 135884 the total institutional shares. 12080894 were the shares owned by these institutional investors. In total 2 funds opened new Kindred Biosciences, Inc stakes, 11 increased stakes. There were 12 that closed positions and 16 reduced them.

Longwood Capital Partners Llc is an institutional investor bullish on Kindred Biosciences, Inc, owning 50000 shares as of Q3 2015 for 0.15% of its portfolio. Seth Klarman Baupost Group Llc owns 3013848 shares or 0.26% of its portfolio. CT Sarissa Capital Management Lp have 0.88% of their stock portfolio for 689091 shares. Further, Jackson Park Capital Llc reported stake worth 0.26% of its US stock portfolio. The CA Ecor1 Capital Llc owns 1323431 shares. Kindred Biosciences, Inc is 3.13% of the manager’s US portfolio.

Business Profile

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Seth Klarman’s Baupost Group LlcMa website.

Insitutional Activity: The institutional sentiment increased to 3.13 in Q2 2016. Its up 2.48, from 0.65 in 2016Q1. The ratio is positive, as 3 funds sold all Kindred Biosciences Inc shares owned while 5 reduced positions. 4 funds bought stakes while 21 increased positions. They now own 25.54 million shares or 107.22% more from 12.33 million shares in 2016Q1.

Osborn Rohs Williams & Donohoe last reported 0.04% of its portfolio in the stock. Blackrock Grp Limited holds 14,850 shares or 0% of its portfolio. Wells Fargo And Co Mn owns 2,989 shares or 0% of their US portfolio. Blackrock Investment Mngmt Ltd holds 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 2,994 shares. Blackrock Japan Limited has 0% invested in the company for 3,327 shares. Blackrock Fund Advisors holds 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 42,936 shares. Ecor1 Limited Co accumulated 2% or 1.43M shares. Lpl Fincl Llc reported 13,925 shares or 0% of all its holdings. Commercial Bank Of Montreal Can accumulated 18 shares or 0% of the stock. Prudential Incorporated holds 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 55,700 shares. Fmr Limited Liability has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Blackrock Institutional Na has 62,182 shares for 0% of their US portfolio. The Massachusetts-based Baupost Group Inc Ltd Liability Company Ma has invested 0.14% in Kindred Biosciences Inc (NASDAQ:KIN). The New Jersey-based Jacobs Levy Equity Management Inc has invested 0% in Kindred Biosciences Inc (NASDAQ:KIN). Nationwide Fund Advsrs accumulated 0% or 8,600 shares.

Analysts await Kindred Biosciences Inc (NASDAQ:KIN) to report earnings on November, 14. They expect $-0.36 EPS, 0.00% or $0.00 from last year’s $-0.36 per share. After $-0.25 actual EPS reported by Kindred Biosciences Inc for the previous quarter, Wall Street now forecasts 44.00% negative EPS growth.

The stock increased 0.93% or $0.05 on November 9, hitting $5.4. About 10,938 shares traded hands. Kindred Biosciences Inc (NASDAQ:KIN) has risen 40.42% since April 7, 2016 and is uptrending. It has outperformed by 35.64% the S&P500.

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The company has a market cap of $107.41 million. The Firm is focused on developing therapies for pets. It currently has negative earnings. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses.

Kindred Biosciences Inc (NASDAQ:KIN) Ratings Coverage

Out of 2 analysts covering Kindred Biosciences (NASDAQ:KIN), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Kindred Biosciences has been the topic of 2 analyst reports since November 17, 2015 according to StockzIntelligence Inc. The stock has “Market Perform” rating given by BMO Capital Markets on Tuesday, November 17. The company was initiated on Tuesday, November 1 by Ladenburg Thalmann.

More notable recent Kindred Biosciences Inc (NASDAQ:KIN) news were published by: Prnewswire.com which released: “Kindred Biosciences Announces Second Quarter 2016 Financial Results” on August 08, 2016, also Prnewswire.com with their article: “Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference” published on September 20, 2016, Quotes.Wsj.com published: “News Kindred Biosciences Inc.KIN” on December 07, 2013. More interesting news about Kindred Biosciences Inc (NASDAQ:KIN) were released by: Prnewswire.com and their article: “Kindred Biosciences Submits New Animal Drug Application Technical Section for …” published on August 22, 2016 as well as Prnewswire.com‘s news article titled: “Kindred Biosciences Submits Final Major New Animal Drug Application Technical …” with publication date: September 30, 2016.

According to Zacks Investment Research, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.”

KIN Company Profile

Kindred Biosciences, Inc., incorporated on September 25, 2012, is a development-stage biopharmaceutical company. The Firm is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Firm is developing product candidates for over 20 indications and focused on small molecule products, and canine and feline biologics products. The Company’s biologic product candidates are based on therapies and targets, for which products have been commercialized for humans. The Firm is developing antibodies that target canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment